Neurocrine Biosciences, Inc. Financials

Market Capitalization $14.94 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	39.35
Forward PE	23.76
Price to Sales TTM	$6.66
Price to Book MRQ	$5.49
Enterprise to Revenue	6.24
Enterprise to EBITDA	22.29

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	17.21%
Operating Margin	29.71%
Return on Assets TTM	11.80%
Return on Equity TTM	16.35%

Income Statement

Revenue TTM	$2,242,800,128
Revenue per Share TTM	$22.42
Quarterly Revenue Growth	24.70%
Gross Profit TTM	$1,526,599,936
EBITDA	$608,500,000
Net Income to Common TTM	$385,900,000
Diluted EPS TTM	$3.75
Quarterly Earnings Growth YoY	56.20%

Balance Sheet

Total Cash MRQ	$1,228,000,000
Total Cash per Share MRQ	$12.13
Total Debt MRQ	$
Total Debt to Equity MRQ	10.53
Current Ratio MRQ	4.37
Book Value per Share MRQ	$26.87

Cash Flow

Operating Cash Flow TTM	$476,400,000
Levered Free Cash Flow TTM	$328,062,496

NBIX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	101,247,000
Float Shares	100,094,721
Avg 10 Volume	943,920
Avg 30 Volume	None
Shares Short	3,349,662
Short Ratio	3.49
Short % of Shares	3.87%
% Held by Insiders	0.99%
% Held by Institutions	94.88%

Stock Price Summary

Beta	0.35
Fifty Two Week Low	$110.95
Fifty Two Week High	$157.98
Fifty Two Week Change	4.38%
Day 50 MA	$132.40
Day 200 MA	$133.08

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	1995-12-29
Last Split Factor
Last Split Date